Document is current
Any future updates will be listed below
-
Authors
Hopiavuori, Blake R.
Deák, Ferenc
Wilkerson, Joseph L.
Brush, Richard S.
Rocha-Hopiavuori, Nicole A.
Hopiavuori, Austin R.
Ozan, Kathryn G.
Sullivan, Michael T.
Wren, Jonathan D.
Georgescu, Constantin
Szweda, Luke
Awasthi, Vibhudutta
Towner, Rheal
Sherry, David M.
Anderson, Robert E.
Agbaga, Martin-Paul
-
Funding
Funding for this research was provided by:
National Eye Institute (R01EY00871)
National Eye Institute (R01EY04149)
National Eye Institute (P30EY021725)
National Institute of Neurological Disorders and Stroke (R21NS090117)
National Institute of Neurological Disorders and Stroke (F31NS089358)
Reynolds Oklahoma Center on Aging (Collaborative Grant)
Reynolds Oklahoma Center on Aging (Pre-doctoral Fellowship)
Research to Prevent Blindness (Departmental)
Presbyterian Health Foundation
Knights Templar Eye Foundation
BrightFocus Foundation
- License Information
-
More Information
Article History
Received: 17 October 2017
Accepted: 7 November 2017
First Online: 22 November 2017
Compliance with Ethical Standards
:
: Dr. Hopiavuori, Dr. Anderson, Dr. Agbaga, and Mr. Brush have a US Patent application (US20170014365) for the use of VLC-SFA in the treatment of human disease.
